Ticiana Leal

Department of Hematology and Medical Oncology
Associate Professor

ticiana.a.leal@emory.edu

Overview

Board certified in medical oncology and palliative care, Dr. Ticiana Leal specializes in caring for patients with lung cancer, mesothelioma and thymic malignancies at Winship Cancer Institute .

Dr. Leal holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, Eastern Cooperative Oncology Group, European Society of Medical Oncology, Society for Immunotherapy of Cancer, and International Association for the Study of Lung Cancer. She is the NCI LUNG-MAP Chair, ECOG-ACRIN representative.

Before joining Emory, Dr. Leal was a member of the faculty at UW Carbone Cancer Center in Madison, Wisconsin, where she served as team leader of the Thoracic Malignancies Disease Oriented Team.

Dr. Leal received her medical degree from Federal University of Ceara in Fortaleza, Brazil. She completed her residency in internal medicine at Weiss Memorial Hospital in Chicago, Illinois. She completed a fellowship in geriatric medicine atthe University of Illinois at Chicago, and a fellowship in medical oncology at theUniversity of Wisconsin Hospitals and Clinics in Madison, Wisconsin.

Dr. Leal's clinical research focuses on clinical trials of chemotherapy and/or immunotherapy agents to treat cancers of the lung. She has authored or coauthored numerous peer-reviewed original research articles, book chapters and posters. She serves as associate editor and as a member of the executive editorial board of The Journal of the National Comprehensive Cancer Network. She also serves as Lung Cancer Section Editor of Current Treatment Options in Oncology and on the editorial advisory boards of Cancer and The Brazilian Journal of Oncology.

Academic Appointment

Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from Federal University of Ceara

Research

Publications

Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
Future Oncol Volume: 21 Page(s): 63 - 71
01/01/2025 Authors: Higgins JP; Carlisle JW; Moniri NH; Gupta S; Oduah EI; Leal T
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
J Thorac Oncol Volume: 20 Page(s): 109 - 118
01/01/2025 Authors: Nassar AH; Jayakrishnan R; Feng J; Shepherd F; Adib E; Cheung JM; Lin JJ; Liu Y; Lin SH; Parikh K
Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.
iScience Volume: 27 Page(s): 111133
11/15/2024 Authors: Sharma R; Sharma S; Shriwas P; Mehta L; Vu AH; Mouw JK; Koo J; Huang C; Matsuk VY; Tucker-Burden C
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
J Exp Med Volume: 221
11/04/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y
Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States.
JCO Glob Oncol Volume: 10 Page(s): e2400138
09/01/2024 Authors: Liu SV; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Leal TA
Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade.
J Clin Oncol Volume: 42 Page(s): 2367 - 2371
07/10/2024 Authors: Carlisle J; Liu Y; Leal T
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best.
Cancer Volume: 130 Page(s): 1910 - 1912
06/01/2024 Authors: Leal TA; Ramalingam SS
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol Volume: 19 Page(s): 928 - 940
06/01/2024 Authors: Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.
Int J Radiat Oncol Biol Phys Volume: 118 Page(s): 1481 - 1489
04/01/2024 Authors: Bassetti MF; Morris BA; Sethakorn N; Lang JM; Schehr JL; Zhao SG; Morris ZS; Buehler D; Eickhoff JC; Harari PM
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
J Clin Invest Volume: 134
03/07/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
JCO Glob Oncol Volume: 10 Page(s): e2300483
03/01/2024 Authors: Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Ann Oncol Volume: 35 Page(s): 66 - 76
01/01/2024 Authors: Borghaei H; de Marinis F; Dumoulin D; Reynolds C; Theelen WSME; Percent I; Gutierrez Calderon V; Johnson ML; Madroszyk-Flandin A; Garon EB
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
Cancer Volume: 129 Page(s): 3713 - 3723
08/01/2022 Authors: McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
Lancet Oncol Volume: 24 Page(s): e454
12/01/2023 Authors: Leal T; Langer C
Advancing immunotherapy in small cell lung cancer.
Cancer Volume: 129 Page(s): 3525 - 3534
11/15/2023 Authors: Carlisle JW; Leal T
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Lancet Oncol Volume: 24 Page(s): 1002 - 1017
09/01/2023 Authors: Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Volume: 7 Page(s): e2300218
09/01/2023 Authors: Vaidya R; Unger JM; Qian L; Minichiello K; Herbst RS; Gandara DR; Neal JW; Leal TA; Patel JD; Dragnev KH
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
J Thorac Oncol Volume: 18 Page(s): 907 - 921
07/01/2023 Authors: He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA
Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.
Am Soc Clin Oncol Educ Book Volume: 43 Page(s): e390794
05/01/2023 Authors: Fernandez-Cuesta L; Sexton-Oates A; Bayat L; Foll M; Lau SCM; Leal T
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Cancer Volume: 129 Page(s): 1319 - 1350
05/01/2023 Authors: Villaruz LC; Blumenschein GR; Otterson GA; Leal TA
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Clin Lung Cancer Volume: 24 Page(s): 228 - 234
05/01/2023 Authors: Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Cancer Volume: 129 Page(s): 264 - 271
01/15/2023 Authors: Salous T; Shukla NA; Althouse SK; Perkins SM; Furqan M; Leal T; Traynor AM; Feldman LE; Hanna NH; Durm GA
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med Volume: 388 Page(s): 44 - 54
01/05/2023 Authors: Yaeger R; Weiss J; Pelster MS; Spira AI; Barve M; Ou S-HI; Leal TA; Bekaii-Saab TS; Paweletz CP; Heavey GA
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy.
Expert Rev Anticancer Ther Volume: 23 Page(s): 817 - 833
01/01/2023 Authors: Leal T; Socinski MA
A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.
Clin Lung Cancer Volume: 23 Page(s): 578 - 584
11/01/2022 Authors: Ardeshir-Larijani F; Althouse SK; Leal T; Feldman LE; Hejleh TA; Patel M; Gentzler RD; Miller AR; Hanna NH
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Clin Lung Cancer Volume: 23 Page(s): e400 - e404
11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Cancer Med Volume: 11 Page(s): 3969 - 3981
11/01/2022 Authors: Leal TA; Sharifi MN; Chan N; Wesolowski R; Turk AA; Bruce JY; O'Regan RM; Eickhoff J; Barroilhet LM; Malhotra J
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.
Radiother Oncol Volume: 174 Page(s): 133 - 140
09/01/2022 Authors: McCall NS; McGinnis HS; Janopaul-Naylor JR; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal T
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
J Clin Oncol Volume: 40 Page(s): 2530 - 2538
08/10/2022 Authors: Ou S-HI; Jnne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C
Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes.
J Clin Oncol Volume: 40 Page(s): 2285 - 2287
07/20/2022 Authors: Leal TA; Dahlberg SE; Ramalingam SS
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer.
Cell Rep Med Volume: 3 Page(s): 100691
07/01/2022 Authors: Leal TA; Ramalingam SS
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Nat Med Volume: 28 Page(s): 939 - 945
05/01/2022 Authors: Kim ES; Velcheti V; Mekhail T; Yun C; Shagan SM; Hu S; Chae YK; Leal TA; Dowell JE; Tsai ML
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer.
Biomark Res Volume: 10 Page(s): 26
10/25/2022 Authors: Schehr JL; Sethakorn N; Schultz ZD; Hernandez CI; Bade RM; Eyzaguirre D; Singh A; Niles DJ; Henderson L; Warrick JW
Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound.
Front Rehabil Sci Volume: 3 Page(s): 982949
01/01/2022 Authors: Lortie J; Rush B; Osterbauer K; Colgan TJ; Tamada D; Garlapati S; Campbell TC; Traynor A; Leal T; Patel V
Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound.
Front Rehabil Sci Volume: 3 Page(s): 896114
01/01/2022 Authors: Lortie J; Rush B; Osterbauer K; Colgan TJ; Tamada D; Garlapati S; Campbell TC; Traynor A; Leal T; Patel V
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts.
Mol Cancer Ther Volume: 20 Page(s): 2129 - 2139
11/01/2021 Authors: Baschnagel AM; Elnaggar JH; VanBeek HJ; Kromke AC; Skiba JH; Kaushik S; Abel L; Clark PA; Longhurst CA; Nickel KP
The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers
Volume: 16 Page(s): S879 - S879
10/18/2021 Authors: Smeltzer M; Bunn B; Choi YS; Coate L; Corona-Cruz J; Drilon A; Duma N; Edelman M; Fidler MJ; Gadgeel S
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
J Thorac Oncol Volume: 16 Page(s): 1559 - 1569
09/01/2021 Authors: Malhotra J; Nikolinakos P; Leal T; Lehman J; Morgensztern D; Patel JD; Wrangle JM; Curigliano G; Greillier L; Johnson ML
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score 50.
J Clin Oncol Volume: 39 Page(s): 2339 - 2349
07/20/2021 Authors: Reck M; Rodrguez-Abreu D; Robinson AG; Hui R; Csszi T; Flp A; Gottfried M; Peled N; Tafreshi A; Cuffe S
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
J Clin Oncol Volume: 39 Page(s): 2327 - 2338
07/20/2021 Authors: Boyer M; endur MAN; Rodrguez-Abreu D; Park K; Lee DH; iin I; Yumuk PF; Orlandi FJ; Leal TA; Molinier O
Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS >= 50%: KEYNOTE-598
Volume: 16 Page(s): S61 - S62
03/19/2021 Authors: Boyer M; Sendur MAN; Rodriguez-Abreu D; Park K; Lee DH; Cicin I; Yumuk PF; Orlandi F; Leal T; Molinier O
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
J Natl Compr Canc Netw Volume: 19 Page(s): 254 - 266
03/02/2021 Authors: Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; D'Amico TA
Tumor Treating Fields (150 kHz) Concurrent with Immune Check Point Inhibitors for Stage 4 Non-Small Cell Lung Cancer (NSCLC) in Phase 3 LUNAR Study
Volume: 16 Page(s): S651 - S651
03/01/2021 Authors: Leal T; Bueno R; Havel L; Ward J
Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Clin Lung Cancer Volume: 22 Page(s): 110 - 119
03/01/2021 Authors: Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
J Clin Oncol Volume: 39 Page(s): 619 - 630
02/20/2021 Authors: Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M
Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases.
Sci Rep Volume: 11 Page(s): 2520
01/28/2021 Authors: Baschnagel AM; Kaushik S; Durmaz A; Goldstein S; Ong IM; Abel L; Clark PA; Gurel Z; Leal T; Buehler D
Immunotherapy Combined with Stereotactic Radiotherapy Improves Intracranial Control for Non-Small Cell Lung Cancer
Volume: 108 Page(s): E97 - E97
11/01/2020 Authors: Enright T; Witt JS; Burr A; Yadav P; Leal TA; Baschnagel AM
TUMOR TREATING FIELDS (TTFIELDS, 150 KHZ) CONCURRENT WITH STANDARD OF CARE TREATMENT FOR STAGE 4 NON-SMALL CELL LUNG CANCER (NSCLC) IN PHASE 3 LUNAR STUDY
Volume: 8 Page(s): A223 - A223
11/01/2020 Authors: Leal T; Bueno R; Havel L; Ward J
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.
Cancer Med Volume: 9 Page(s): 7511 - 7523
10/01/2020 Authors: Steffen McLouth LE; Zhao F; Owonikoko TK; Feliciano JL; Mohindra NA; Dahlberg SE; Wade JL; Srkalovic G; Lash BW; Leach JW
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis.
Curr Med Res Opin Volume: 36 Page(s): 1497 - 1505
09/01/2020 Authors: Leal TA; Argento AC; Bhadra K; Hogarth DK; Grigorieva J; Hartfield RM; McDonald RC; Bonomi PD
Analytical validation and preliminary clinical utility of PD-L1 and HLA I expression profiling of circulating tumor cells using automated exclusion-based sample preparation technology
Volume: 26 Page(s): 30 - 31
06/01/2020 Authors: Schehr JL; Schultz ZD; Hernandez CI; Mannino MC; Warrick JW; Leal TA; Beebe DJ; Lang JM
Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay.
J Immunother Cancer Volume: 8
06/01/2020 Authors: Lema DA; Jankowska-Gan E; Sethakorn N; Burlingham W; Leal T
Identification of Muscle Wasting in Lung Cancer using MRI Proton Density Fat Fraction and Ultrasound
Volume: 34
04/01/2020 Authors: Osterbauer K; Lortie J; Rush B; Colgan T; Lee K; Leal T; Reeder S; Kuchnia A
Impower133: Updated Overall Survival (OS) Analysis of First-Line (1L) Atezolizumab (ATEZO) plus Carboplatin plus Etoposide in Extensive-Stage SCLC (ES-SCLC)
Volume: 43 Page(s): 233 - 233
02/01/2020 Authors: Reck M; Liu SV; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
J Thorac Oncol Volume: 14 Page(s): 1901 - 1911
11/01/2019 Authors: Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR
Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
Volume: 14 Page(s): S1171 - S1172
11/01/2019 Authors: Leal T; Wakelee H; Reckamp KL; Chiappori A; Oxnard GR; Waqar SN; Patel SP; Blumenschein GR; Neal JW; Harrow K
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
Volume: 14 Page(s): S406 - S406
10/01/2019 Authors: Leal T; Lang J; Schehr J; Schneider K; Wheeler D; Malhotra J; Bertino E; Eickhoff J; Traynor A
Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
Volume: 14 Page(s): S566 - S566
10/01/2019 Authors: Wakelee H; Reckamp K; Leal T; Chiappori A; Waqar S; Zeman K; Neal J; Liang C; Harrow K; Holzhausen A
New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting
Volume: 14 Page(s): S1018 - S1019
10/01/2019 Authors: Mccune S; Ton T; Whipple S; Induru R; Horn L; Percent I; Mekhail T; Goldschmidt J; Leal T; Macvicar G
Interim Safety Analysis of the Phase IB Trial of SBRT to All Sites of Oligometastatic NSCLC Combined with Durvalumab and Tremelimumab
Volume: 14 Page(s): S248 - S249
10/01/2019 Authors: Leal T; Lang J; Morris Z; Eickhoff J; Traynor A; Campbell T; Baschnagel A; Bassetti M
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?
Transl Lung Cancer Res Volume: 8 Page(s): S153 - S162
09/01/2019 Authors: Nesbit EG; Leal TA; Kruser TJ
Implementing value assessment in oncology practice: A single-center experience.
J Oncol Pharm Pract Volume: 25 Page(s): 947 - 953
06/01/2019 Authors: Saunders K; Mably MS; Shull SS; Jones H; Leal TA; Bergsbaken JJ
Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.
J Oncol Pharm Pract Volume: 25 Page(s): 954 - 960
06/27/2019 Authors: Renna CE; Dow EN; Bergsbaken JJ; Leal TA
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Volume: 37
05/20/2019 Authors: Turk AA; Leal T; Chan N; Wesolowski R; Spencer KR; Malhotra J; Lang JM; McNeel DG; O'Regan R; Mehnert JM
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
J Clin Oncol Volume: 37 Page(s): 222 - 229
01/20/2019 Authors: Owonikoko TK; Dahlberg SE; Sica GL; Wagner LI; Wade JL; Srkalovic G; Lash BW; Leach JW; Leal TB; Aggarwal C
Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
Volume: 13 Page(s): S924 - S925
10/01/2018 Authors: Leal T; Schehr J; Kamisnki A; Campbell T; Traynor A; Lang J
Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC)
Volume: 29
10/01/2018 Authors: Wakelee H; Reckamp KL; Leal TA; Patel SP; Blumenschein G; Shum E; Nieva J; Oxnard G; Sanborn RE; Waqar S
Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population
Volume: 13 Page(s): S615 - S615
10/01/2018 Authors: Kratz J; Harmon G; Kosoff D; Wubben D; Laughlin R; Traynor A; Deming D; Burkard M; Leal T
Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
Volume: 13 Page(s): S156 - S156
09/01/2018 Authors: Leal T; Wakelee H; Reckamp K; Waqar S; Patel S; Blumenschein G; Neal J; Harrow K; Holzhausen A; Liang C
Identifying Resistance to Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in NSCLC
Volume: 13 Page(s): S160 - S160
09/01/2018 Authors: Leal T; Schehr J; Kaminski A; Campbell T; Traynor A; Lang J
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
J Natl Compr Canc Netw Volume: 16 Page(s): 807 - 821
07/01/2018 Authors: Ettinger DS; Aisner DL; Wood DE; Akerley W; Bauman J; Chang JY; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower M
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Clin Cancer Res Volume: 24 Page(s): 2771 - 2779
06/15/2018 Authors: Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L
Exclusive Liquid Repellency: An Open Multi-Liquid-Phase Technology for Rare Cell Culture and Single-Cell Processing.
ACS Appl Mater Interfaces Volume: 10 Page(s): 17065 - 17070
05/23/2018 Authors: Li C; Yu J; Schehr J; Berry SM; Leal TA; Lang JM; Beebe DJ
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Volume: 36
05/20/2018 Authors: Turk AA; Leal TAB; Chan N; Wesolowski R; O'Regan R; Burkard ME; Tevaarwerk A; Rice L; Campbell TC; Bruce JY
Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
J Thorac Dis Volume: 10 Page(s): S422 - S432
02/01/2018 Authors: Leal TA; Ramalingam SS
Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors
Volume: 12 Page(s): S1803 - S1803
11/01/2017 Authors: Leal T; Campbell T; Mapes A; Schneider K; Staab MJ; Velastegui K; Christensen J; Chen I; Traynor A
Stereotactic Body Radiotherapy to All Sites of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Combined with Durvalumab and Tremelimumab
Volume: 12 Page(s): S2288 - S2288
11/01/2017 Authors: Bassetti M; Lang J; Morris Z; Morris B; Eickhoff J; Traynor A; Campbell T; Matkowskyj K; Baschnagel A; Leal T
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw Volume: 15 Page(s): 504 - 535
04/01/2017 Authors: Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Volume: 77
02/01/2017 Authors: Turk A; Chan N; Leal T; O'Regan R; Tevaarwerk A; Rice L; Campbell T; Barroilhet L; Mehnert J; Eickhoff J
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board.
JCO Precis Oncol Volume: 1
01/01/2017 Authors: Burkard ME; Deming DA; Parsons BM; Kenny PA; Schuh MR; Leal T; Uboha N; Lang JM; Thompson MA; Warren R
Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC
Volume: 11 Page(s): S209 - S210
10/01/2016 Authors: Leal T; Wakelee H; Infante J; Blumenschein G; Reckamp K; Carter C; Waqar S; Gockerman J; Lovly C; Dukart G
Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK plus NSCLC
Volume: 11 Page(s): S176 - S177
10/01/2016 Authors: Leal T; Wakelee H; Infante J; Blumenschein G; Reckamp K; Carter C; Waqar S; Gockerman J; Lovly C; Dukart G
A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
Volume: 76
02/15/2016 Authors: Mullvain JA; Leal T; Eickhoff J; Kolesar JM; Liu G; DiPaola RS; Wisinski KB
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
PLoS One Volume: 11 Page(s): e0159397
01/01/2016 Authors: Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K
Health Literacy and Health-Related Quality of Life Among a Population-Based Sample of Cancer Patients.
J Health Commun Volume: 20 Page(s): 1320 - 1329
01/01/2015 Authors: Halverson JL; Martinez-Donate AP; Palta M; Leal T; Lubner S; Walsh MC; Schaaf Strickland J; Smith PD; Trentham-Dietz A
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Cancer Chemother Pharmacol Volume: 68 Page(s): 1439 - 1447
12/01/2011 Authors: Leal TB; Remick SC; Takimoto CH; Ramanathan RK; Davies A; Egorin MJ; Hamilton A; LoRusso PA; Shibata S; Lenz H-J
Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.
Curr Cancer Ther Rev Volume: 7 Page(s): 319 - 327
11/01/2011 Authors: Leal T; Chang JE; Mehta M; Robins HI
Preoperative Evaluation and Preparation in the Elderly Thoracic Surgery Patient
Page(s): 465 - 473
01/01/2011 Authors: Leal T; LoConte NK; Kothari A; Weigel TL
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.
Thrombosis Volume: 2011 Page(s): 530183
01/01/2011 Authors: Chao BH; Lepeak L; Leal T; Robins HI
Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience.
J Gastrointest Oncol Volume: 2 Page(s): 85 - 92
01/01/2011 Authors: Loconte NK; Williamson A; Gayle A; Weiss J; Leal T; Cetnar J; Mohammed T; Tevaarwerk A; Jones N
Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
Clin Breast Cancer Volume: 10 Page(s): 471 - 476
12/01/2010 Authors: Leal T; Tevaarwerk A; Love R; Stewart J; Binkley N; Eickhoff J; Parrot B; Mulkerin D
A phase I study of r-(-)-gossypol (AT-101, NSC 726190) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC)
Volume: 28
05/20/2010 Authors: Leal TA; Schelman WR; Traynor AM; Kolesar J; Mamocha RM; Eickhoff JC; Alberti DB; Takebe N; Wilding G
Pharmacokinetic and Pharmacodynamic Monitoring in Clinical Trials: When Is It Needed?
Page(s): 251 - 259
01/01/2010 Authors: Leal T; Kolesar JM
Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report.
Cancer Chemother Pharmacol Volume: 65 Page(s): 399 - 401
01/01/2010 Authors: Leal T; Robins HI
A phase I study of R-(-)- gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC)
Volume: 27
05/20/2009 Authors: Leal TB; Schelman W; Traynor A; Kolesar J; Marnosha R; Eickhoff J; Alberti D; Wilding G
Quality of life in the older patient with pancreatic cancer
Volume: 55 Page(s): S72 - S72
04/01/2007 Authors: Leal TA; Perez F; Mehta DA; Jurivich DA

Directory section navigation

Profile